Polymer microneedle for treating acute attack of gout and preparation method of polymer microneedle

Abstract

The invention discloses a polymer microneedle for treating acute attack of gout and a preparation method of the polymer microneedle. According to the polymer microneedle, a medicinal preparation which is wrapped by a nano material and contains an effective dose of IL-1 receptor antagonist is embedded into a needle tip; the medicinal preparation contains 0.005-0.05 part by weight of the IL-1 receptor antagonist, 0.05-0.15 part by weight of sodium phosphate, 0.0025-0.025 part by weight of mannitol and 0.005-0.025 part by weight of sodium chloride. According to the microneedle, a microneedle patch is directly adhered to an affected part, so that the microneedle is simple and convenient to use; the nano-material is used for coating and slow release, so that the medicine can fully play a role, has better fixed-point and targeted treatment effects and is higher in drug utilization rate; and the problem that the IL-1 receptor antagonist is short in systemic circulation half-life period and isdifficult to act on an affected part for a long time is solved, and various problems caused by excessive use of the IL-1 receptor antagonist in a systemic way are solved.

Description

technical field [0001] The present application relates to the technical field of gout treatment, in particular to a polymer microneedle for treating acute attacks of gout and a preparation method thereof. Background technique [0002] Gout is a common disease in the world. According to epidemiological statistics, the prevalence rate of hyperuricemia reported in Europe and the United States in the 1990s was 2%-24%, and the prevalence rate of hyperuricemia reported in the United States in 1993 was 10.1%. According to statistics in China in 2008, the overall prevalence rate of hyperuricemia was 13.2-21.04%. The total prevalence of gout around the world is between 0.13-15.3%, and the global annual incidence is between 0.20%-0.35%. The incidence of gout and hyperuricemia in European and American countries is significantly higher than that in other countries, and it is increasing year by year. Among them, the prevalence of gout patients in the United States is about 3.9%. Accord...

AI Technical Summary

Problems solved by technology

However, some patients only partially respond to this treatment, and often relapse within 1-6 weeks after discontinuation

Moreover, the biological half-life of anakinra is short, and daily subcutaneous administration is required, so it is not suitable for the prevention of seizures; in addition, the half-life of anakinra in the systemic circulation is short, which greatly limits its target efficacy. Maximize drug action in tissue

Images